Stem cell therapies have been shown to improve clinical signs of canine OA, to promote healing in tendinopathies and improve the structural damage caused by the disease. In canine hip OA, MSC therapy has also demonstrated superior efficacy results at 6 months when compared with PRGF (PRP).
In March 2014, Prof John Innes and Dr Ben Walton published a review of the published pre-clinical and early clinical data investigating the role of stem in small animal medicine. The authors predicted in their conclusion was that :
“Interest in MSCs is set to continue. In small animal orthopaedics at least, perhaps the most promising application is in the treatment of joint disease. Anecdotal reports of response to intra-articular injections of MSCs for the management of OA are encouraging. It is anticipated that reports concerning the safety and efficacy of MSCs will be forthcoming in the near future.”
Daniel please attach Attachment " John Innes and Ben Walton " from the email in here- using the iconography
Just two years later, orthopaedic veterinary specialist, Assistant Professor Karen Perry, published a review in April 2016 in which she examined the most up to date, peer-reviewed literature on the use of stem cell injections for degenerative joint disease.
Interestingly, the author only describes the process for adipose-derived “ same day” or Stromal Vascular Fraction ( SVF) therapy, which is very different from our culture-expanded stem cell therapy, as illustrated by the posterattached below “ Stem Cell Therapies are Not all the Same”. This review concluded that “current evidence supports the use of stem cells in (OA) patients that have failed to respond adequately to more conventional therapies” and “may offer an option whereby (salvage) surgical management can either be delayed or avoided without condemning the patient to a life of ongoing discomfort”. https://www.vettimes.co.uk/article/using-cellular-therapies-for-canine-joint-treatment-part-1
Daniel please attach Karen Perry here….
More robust evidence is now starting to emerge from the many ongoing stem cell trials in humans and in dogs, with 2017 promising to be an interesting year as the data from these controlled studies starts to appear in the scientific press. The first of these, a randomised, placebo-controlled clinical study in moderate to severe canine OA was published in September 2016. The attached paper by Robert Harman et al, describes the most significant study to date: a randomized, placebo-controlled, confirmatory study, designed to support a Market Authorization submission to theUS Food and Drug Administration. This study has provided strong evidence of a significant clinical effect following a single injection of allogeneic, culture –expanded stem cells in moderate to severe canine OA. www.ncbi.nlm.nih.gov/pmc/articles/PMC5025432/ and Robert Harman attached here !!